Notably, recent updates from the phase III MONALEESA-3 trial [10, 11] confirmed that ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with ER + HER2 − metastatic BC [11, 12]. Here, ERBB2 is linked to breast cancer.